Kardigan (KARD) Competitors

$11.49 -1.03 (-8.23%)
As of 11/20/2026 03:59 PM Eastern

KARD vs. SRRK, DNTH, COGT, EWTX, and TVTX

Should you buy Kardigan stock or one of its competitors? Kardigan's main competitors and comparable companies include Scholar Rock (SRRK), Dianthus Therapeutics (DNTH), Cogent Biosciences (COGT), Edgewise Therapeutics (EWTX), and Travere Therapeutics (TVTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kardigan compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Kardigan (NASDAQ:KARD) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Kardigan has lower revenue, but higher earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Kardigan, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scholar Rock$570K10,302.06-$377.94M-$3.36N/A
KardiganN/AN/A-$191.94M-$3.52N/A

Kardigan's return on equity of -152.99% beat Scholar Rock's return on equity.

Company Net Margins Return on Equity Return on Assets
Scholar RockN/A -175.27% -86.66%
Kardigan N/A -152.99%-46.19%

91.1% of Scholar Rock shares are held by institutional investors. 10.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Scholar Rock presently has a consensus price target of $69.50, suggesting a potential upside of 44.40%. Kardigan has a consensus price target of $41.00, suggesting a potential upside of 256.83%. Given Kardigan's stronger consensus rating and higher probable upside, analysts clearly believe Kardigan is more favorable than Scholar Rock.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scholar Rock
2 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
3 Strong Buy rating(s)
2.82
Kardigan
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.90

In the previous week, Kardigan had 8 more articles in the media than Scholar Rock. MarketBeat recorded 15 mentions for Kardigan and 7 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.33 beat Kardigan's score of 0.23 indicating that Scholar Rock is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Scholar Rock
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kardigan
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Scholar Rock beats Kardigan on 7 of the 13 factors compared between the two stocks.

How does Kardigan compare to Dianthus Therapeutics?

Kardigan (NASDAQ:KARD) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

47.5% of Dianthus Therapeutics shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Kardigan had 9 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 15 mentions for Kardigan and 6 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.43 beat Kardigan's score of 0.23 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kardigan
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Dianthus Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Dianthus Therapeutics has higher revenue and earnings than Kardigan. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Kardigan, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KardiganN/AN/A-$191.94M-$3.52N/A
Dianthus Therapeutics$2.04M2,333.83-$162.34M-$3.99N/A

Kardigan currently has a consensus target price of $41.00, suggesting a potential upside of 256.83%. Dianthus Therapeutics has a consensus target price of $128.77, suggesting a potential upside of 52.30%. Given Kardigan's higher possible upside, analysts plainly believe Kardigan is more favorable than Dianthus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kardigan
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.90
Dianthus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
3.00

Kardigan has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -7,436.50%. Dianthus Therapeutics' return on equity of -19.68% beat Kardigan's return on equity.

Company Net Margins Return on Equity Return on Assets
KardiganN/A -152.99% -46.19%
Dianthus Therapeutics -7,436.50%-19.68%-18.95%

Summary

Dianthus Therapeutics beats Kardigan on 9 of the 13 factors compared between the two stocks.

How does Kardigan compare to Cogent Biosciences?

Kardigan (NASDAQ:KARD) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, Kardigan had 9 more articles in the media than Cogent Biosciences. MarketBeat recorded 15 mentions for Kardigan and 6 mentions for Cogent Biosciences. Kardigan's average media sentiment score of 0.23 beat Cogent Biosciences' score of 0.21 indicating that Kardigan is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kardigan
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cogent Biosciences
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Cogent Biosciences' return on equity of -79.74% beat Kardigan's return on equity.

Company Net Margins Return on Equity Return on Assets
KardiganN/A -152.99% -46.19%
Cogent Biosciences N/A -79.74%-45.67%

Cogent Biosciences is trading at a lower price-to-earnings ratio than Kardigan, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KardiganN/AN/A-$191.94M-$3.52N/A
Cogent BiosciencesN/AN/A-$328.94M-$2.25N/A

Kardigan presently has a consensus target price of $41.00, indicating a potential upside of 256.83%. Cogent Biosciences has a consensus target price of $53.57, indicating a potential upside of 100.49%. Given Kardigan's stronger consensus rating and higher probable upside, research analysts plainly believe Kardigan is more favorable than Cogent Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kardigan
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.90
Cogent Biosciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78

Summary

Kardigan beats Cogent Biosciences on 6 of the 9 factors compared between the two stocks.

How does Kardigan compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Kardigan (NASDAQ:KARD) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Edgewise Therapeutics presently has a consensus price target of $53.58, suggesting a potential upside of 34.40%. Kardigan has a consensus price target of $41.00, suggesting a potential upside of 256.83%. Given Kardigan's stronger consensus rating and higher possible upside, analysts clearly believe Kardigan is more favorable than Edgewise Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edgewise Therapeutics
2 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.58
Kardigan
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.90

Edgewise Therapeutics' return on equity of -7.15% beat Kardigan's return on equity.

Company Net Margins Return on Equity Return on Assets
Edgewise TherapeuticsN/A -7.15% -6.65%
Kardigan N/A -152.99%-46.19%

Kardigan is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edgewise TherapeuticsN/AN/A-$167.79M$8.194.87
KardiganN/AN/A-$191.94M-$3.52N/A

In the previous week, Kardigan had 5 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 15 mentions for Kardigan and 10 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.77 beat Kardigan's score of 0.23 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Edgewise Therapeutics
3 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Kardigan
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Edgewise Therapeutics beats Kardigan on 6 of the 10 factors compared between the two stocks.

How does Kardigan compare to Travere Therapeutics?

Kardigan (NASDAQ:KARD) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

In the previous week, Kardigan had 9 more articles in the media than Travere Therapeutics. MarketBeat recorded 15 mentions for Kardigan and 6 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.33 beat Kardigan's score of 0.23 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kardigan
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Travere Therapeutics
3 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Travere Therapeutics has higher revenue and earnings than Kardigan. Travere Therapeutics is trading at a lower price-to-earnings ratio than Kardigan, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KardiganN/AN/A-$191.94M-$3.52N/A
Travere Therapeutics$490.73M9.19-$25.55M-$1.29N/A

Kardigan has a net margin of 0.00% compared to Travere Therapeutics' net margin of -18.66%. Kardigan's return on equity of -152.99% beat Travere Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
KardiganN/A -152.99% -46.19%
Travere Therapeutics -18.66%-185.69%-17.24%

Kardigan presently has a consensus target price of $41.00, suggesting a potential upside of 256.83%. Travere Therapeutics has a consensus target price of $72.55, suggesting a potential upside of 54.37%. Given Kardigan's stronger consensus rating and higher probable upside, analysts plainly believe Kardigan is more favorable than Travere Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kardigan
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.90
Travere Therapeutics
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77

Summary

Kardigan and Travere Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get Kardigan News Delivered to You Automatically

Sign up to receive the latest news and ratings for KARD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KARD vs. The Competition

MetricKardiganBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.08B$3.92B$7.44B$10.86B
Dividend YieldN/A3.79%2.51%4.69%
P/E Ratio-3.2623.0732.5628.72
Price / SalesN/A15.358.005.34
Price / CashN/A21.9220.2520.77
Price / Book1.884.124.343.51
Net Income-$191.94M-$24.08M$3.51B$394.12M
7 Day Performance-16.86%-9.85%-8.07%-8.97%
1 Month Performance-9.81%-12.77%-10.29%-11.61%
1 Year PerformanceN/A-7.99%-4.70%-11.21%

Kardigan Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KARD
Kardigan
2.3402 of 5 stars
$11.49
-8.2%
$41.00
+256.8%
N/A$1.08BN/AN/A241
SRRK
Scholar Rock
3.1608 of 5 stars
$43.21
+0.1%
$67.67
+56.6%
+19.7%$5.27BN/AN/A289
DNTH
Dianthus Therapeutics
2.1358 of 5 stars
$91.81
-0.7%
$128.77
+40.3%
+104.0%$5.21B$2.04MN/A92
COGT
Cogent Biosciences
2.5337 of 5 stars
$28.56
-2.0%
$53.57
+87.6%
-27.3%$5.07BN/AN/A258
EWTX
Edgewise Therapeutics
3.2541 of 5 stars
$45.93
+0.2%
$52.83
+15.0%
+75.9%$5.02BN/A5.61133

Related Companies and Tools


This page (NASDAQ:KARD) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners